Showing 451-460 of 534 results for "".
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- OOTG Webcast: Weathering the Storm and Supporting Staffhttps://modernod.com/news/ootg-webcast-weathering-the-storm-and-supporting-staff/2477488/“Ophthalmology off the Grid” cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, sat down—virtually—with Robert Weinstock, MD, and Elizabeth Yeu, MD, on March 27 to discuss how the COVID-19 crisis is
- AOA: Changes on the Horizon for Evaluation and Management Serviceshttps://modernod.com/news/aoa-changes-on-the-horizon-for-evaluation-and-management-services/2477202/There has been a lot of information disseminated by various individuals and organizations regarding upcoming changes to coding and reimbursement for evaluation and management services (E/M services). Given the importance of E/M services in patient care, it’s critical that all doctors of opt
- EyeCare4Kids Names Maggie Cline as New CEOhttps://modernod.com/news/eyecare4kids-names-maggie-cline-as-new-ceo/2482838/The non-profit EyeCare4Kids announced the promotion of Maggie Cline, MPH, to Chief Executive Officer (CEO). Ms. Cline joined EyeCare4Kids in 2022 and served as Executive Director Utah, where she oversaw the delivery of more than 50,000 vision services annually at school clinics, community centers
- Perfuse Therapeutics Announces Positive Results from Phase 1/2a Trial of PER-001 Intravitreal Implant in Patients with Glaucomahttps://modernod.com/news/perfuse-therapeutics-announces-positive-results-from-phase-12a-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma/2482794/Perfuse Therapeutics announced positive 24-week results from its completed phase 1/2a trial of PER-001, a first in class endothelin antagonist intravitreal implant for glaucoma. Steven Mansberger, MD, MPH, Chief of Ophthalmology and Director of Gl
- Iantrek Appoints Adam Szaronos as Chief Executive Officerhttps://modernod.com/news/iantrek-appoints-adam-szaronos-as-chief-executive-officer/2482644/Iantrek announced the appointment of Adam Szaronos as its new Chief Executive Officer. Mr. Szaronos succeeds company founder Sean Ianchulev, MD, MPH, who will remain as Chairman of the Board and Chief Medical Officer. “Iantrek has reached an exciting milestone as we transitio
- Forecasting the New Normal: Experts Across Eye Care Discuss COVID-19’s Impacthttps://modernod.com/news/covid-19-forecasting-the-new-normal/2477626/In a recent episode of Ophthalmology Off the Grid, cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, were joined by Iqbal Ike K. Ahmed, MD, FRCSC; John Kitchens, MD; and Justin Schweitzer, OD, to discuss COVID-19’s impact across eye care and share their predictions for how the current
- Experts Provide Advice on How to Handle Staff and Ensure Business Survival When the Practice Closeshttps://modernod.com/news/ootg-webcast-experts-provide-advice-on-how-to-handle-staff-and-ensure-business-survival-when-the-practice-closes/2477517/In the latest episode of Ophthalmology off the Grid, cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, touched base with practice management experts Bruce Maller and Matt Jensen who shed light on key areas of concern for practice leaders. Mr. Maller and Mr. Jensen provide insight on a variet
- New Podcast Addresses COVID-19 Impacthttps://modernod.com/news/new-podcast-addresses-covid-19-impact/2477431/In the latest installment of the Off the Grid podcast, titled “Unprecedented Times,” cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, speak with Steven J. Dell, MD, and Tal Raviv, MD, to discuss the novel coronavirus and its impact on their respective states, practices, and dail
- Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company Growthhttps://modernod.com/news/gyroscope-therapeutics-strengthens-senior-leadership-ahead-of-next-stage-of-company-growth/2477297/Gyroscope Therapeutics announced the strengthening of its leadership team with the hiring of Nadia Waheed, MD, MPH, from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO), and the promotion of Jane Hughes, PhD, formerly VP Translational Research, to Chief Scientific Off